Wilkinson L, et al. - This research incorporated an estimation of the cost per patient achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide and dulaglutide among subjects with type 2 diabetes (T2D) in the USA. The observation made was that the cost of bringing 1 patient to the triple composite endpoint of an HbA1c < 7% without hypoglycemia and no weight gain would be 28% and 68% higher with dulaglutide 1.5 mg compared to once-weekly semaglutide 1.0 mg and dulaglutide 0.75 mg relative to once-weekly semaglutide 0.5 mg, respectively. Hence, better value for money was yielded with once-weekly semaglutide compared to dulaglutide for the treatment of T2D.